Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Freeport-McMoRan Inc (FCX) Price & Performance

ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.

Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.

FCX trades at $61.52, up 1.69% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.60. Revenue growth is steady, and profitability metrics like a 10.34% net income margin and 14.7% ROE reflect operational strength. Recent news highlights FCX's role in the copper market, driven by AI and energy transition demand.

The outlook is positive due to robust copper demand and expansion projects, but risks include commodity price volatility and high debt. Analysts are bullish with a $73.35 consensus price target, implying 19% upside. Investors should weigh strong cash flows and dividend payments against cyclical industry exposure and macroeconomic headwinds.